These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 20035688

  • 1. [Monoclonal antibodies in multiple sclerosis].
    Papeix C, Lubetzki C.
    Med Sci (Paris); 2009 Dec; 25(12):1113-5. PubMed ID: 20035688
    [Abstract] [Full Text] [Related]

  • 2. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 3. [Natalizumab in the treatment of multiple sclerosis].
    Horga A, Horga de la Parte JF.
    Rev Neurol; 2006 Aug; 45(5):293-303. PubMed ID: 17876741
    [Abstract] [Full Text] [Related]

  • 4. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.
    Vermersch P, Kappos L, Gold R, Foley JF, Olsson T, Cadavid D, Bozic C, Richman S.
    Neurology; 2011 May 17; 76(20):1697-704. PubMed ID: 21576685
    [Abstract] [Full Text] [Related]

  • 6. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B, Kappos L.
    Neurodegener Dis; 2008 May 17; 5(1):16-22. PubMed ID: 18075270
    [Abstract] [Full Text] [Related]

  • 7. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
    Johnson KP.
    Neurologist; 2007 Jul 17; 13(4):182-7. PubMed ID: 17622909
    [Abstract] [Full Text] [Related]

  • 8. The role of natalizumab in the treatment of multiple sclerosis.
    Coyle PK.
    Am J Manag Care; 2010 Jun 17; 16(6 Suppl):S164-70. PubMed ID: 20615052
    [Abstract] [Full Text] [Related]

  • 9. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK.
    Arch Neurol; 2006 Oct 17; 63(10):1383-7. PubMed ID: 17030653
    [Abstract] [Full Text] [Related]

  • 10. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis.
    Bennett JL.
    Neurol Res; 2006 Apr 17; 28(3):291-8. PubMed ID: 16687056
    [Abstract] [Full Text] [Related]

  • 11. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis.
    Foley J.
    Am J Manag Care; 2010 Jun 17; 16(6 Suppl):S178-83. PubMed ID: 20615054
    [Abstract] [Full Text] [Related]

  • 12. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.
    Rice GP, Hartung HP, Calabresi PA.
    Neurology; 2005 Apr 26; 64(8):1336-42. PubMed ID: 15851719
    [Abstract] [Full Text] [Related]

  • 13. Treating multiple sclerosis with natalizumab.
    Iaffaldano P, Lucchese G, Trojano M.
    Expert Rev Neurother; 2011 Dec 26; 11(12):1683-92. PubMed ID: 22091593
    [Abstract] [Full Text] [Related]

  • 14. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Neurology; 2008 Sep 02; 71(10):766-73. PubMed ID: 18765653
    [Abstract] [Full Text] [Related]

  • 15. Reactivation of JC virus and development of PML in patients with multiple sclerosis.
    Khalili K, White MK, Lublin F, Ferrante P, Berger JR.
    Neurology; 2007 Mar 27; 68(13):985-90. PubMed ID: 17389301
    [Abstract] [Full Text] [Related]

  • 16. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.
    Steinman L.
    Nat Rev Drug Discov; 2005 Jun 27; 4(6):510-8. PubMed ID: 15931259
    [Abstract] [Full Text] [Related]

  • 17. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
    Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, Gold R.
    N Engl J Med; 2009 Sep 10; 361(11):1075-80. PubMed ID: 19741228
    [Abstract] [Full Text] [Related]

  • 18. [Monoclonal antibodies improve therapy of relapsing multiple sclerosis. Molecular basis and clinical results of anti-VLA4 (natalizumab) therapy].
    Gold R, Hartung HP, Hohlfeld R.
    Dtsch Med Wochenschr; 2006 Jan 05; 131(1-2):31-4. PubMed ID: 16374741
    [No Abstract] [Full Text] [Related]

  • 19. [Natalizumab in multiple sclerosis: unclear patient benefits].
    Schipper JP.
    Ned Tijdschr Geneeskd; 2007 Apr 14; 151(15):852-5. PubMed ID: 17472115
    [Abstract] [Full Text] [Related]

  • 20. [New drugs; natalizumab].
    van Bronswijk H, Dubois EA, van Gerven JM, Cohen AF.
    Ned Tijdschr Geneeskd; 2008 Mar 01; 152(9):499-500. PubMed ID: 18389881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.